- The biotech company Invivyd, which makes the COVID-19 monoclonal antibody Pemgarda, announced this week that it has launched the SPEAR Study Group to explore the drug for Long COVID and post-vaccine syndrome (PVS). The group launched following anecdotal success stories suggesting the drug may help treat Long COVID, and plans to further investigate Pemgarda through clinical research. Members of the group include researchers Michael Peluso, Amy Proal, and David Putrino. “We hope [this study group] will lay the groundwork for future efficacy studies that could deliver real therapeutic options to patients who have waited far too long,” said Peluso in a press release.
- A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with SARS-CoV-2. The study followed 797 participants in Taiwan, including 573 with confirmed COVID-19 cases, infected between June and November 2023, and 224 who were not infected. The authors wrote that children with the disease had “more severe physical and psychological symptoms, family dysfunction, and school-related stress.”
- A new observational study is investigating the relationship between COVID-19 and diabetes. Researchers in San Antonio, Texas are recruiting 213 people with no history of diabetes, including those who were hospitalized with COVID-19 and those who had “mild” COVID-19 but were not hospitalized. The researchers aim to study how diabetes develops after COVID-19, including underlying metabolic issues like insulin resistance. Study contact: Marzieh Salehi, salehi@uthscsa.edu.
One response
[…] The Sick Times: Research updates, July 8 […]